Trimethoprim is a specific inhibitor of dihydrofolate reductase. When added to amino acid supplemented cultures of Escherichia coli, protein, ribonucleic acid (RNA), and deoxyribonucleic acid synthesis are rapidly inhibited. It is shown that thymidylate and purine synthesis must continuously occur if the inhibition is to be maintained. These results are interpreted as demonstrating that in vivo trimethoprim can reduce but not totally inhibit the action of dihydrofolate reductase and therefore reduce the amount of tetrahydrofolate derivatives available for formylmethionyl transfer RNA formylation, purine, and thymidylate synthesis.
The antifolate trimethoprim (TMBP) has been widely used for the isolation of thymine-requiring mutants (14) . Bertino and Stacey proposed that the basis of this selection is the inhibition by TMBP of dihydrofolate reductasc, the enzyme which reduces dihydrofolate (DHF) to tetrahydrofolate (THF; reference 1). The DHF is generated during the synthesis of thymidylate. Hence a cell synthesizing thymidylate in the presence of TMBP should become deficient in THF and unable to grow because of THF requirements for the synthesis of glycine, methionine, purines, and thymidylate ( Fig. 1) . Furthermore, it has been reported that the antifolate can inhibit in vivo protein synthesis in Escherichia coli even in the presence of amino acids, thymidylate, and purines. This has been shown to result from an inability to initiate protein translation due to a lack of formylmethionyl transfer ribonucleic acid (NFmet-tRNA; reference 5). TMBP would cause a shortage of N-Fmet-tRNA by reducing the amount of N '-formyl-THF, the formyl donor of N-Fmet-tRNA. The requirement for a formylated amino acid for the initiation of viral protein synthesis has been investigated with the use of TMBP to reduce the intracellular level of THF derivatives (8, 10) . Our studies with T4 bacteriophage-infected cells experimentally confirmed the proposal of Bertino and Stacey that TMBP is only effective when thymidylate is being synthesized and suggested that even under these conditions an exogenous purine or thymidylate source relieves the inhibition (10) . We have extended our studies to include uninfected E. coli with the object of establishing the in vivo relationships between the synthesis of thymidylate, purines, and protein initiation.
MATERIALS AND METHODS
The following strains of E. coli were used: B, prototrophic; BT-, a thymine-requiring mutant of B; B96, an adenine-requiring mutant of B which lacks phosphoribosyl aminoimidazole carboxamide formyl transferase (7) . M9 growth medium supplemented with 0.1% casein hydrolyzate was used for these experiments. The procedure for growth of cultures has been previously described ( 1) ,ug/ml (36 to 720 uM), the rate of protein synthesis was reduced within 7 min to 10% of the untreated rate. The residual rate is unlikely to represent a population of cells resistant to TMBP because this rate does not increase affer a period of three generations in the presence of TMBP (unpublished data).
Requirement for thymidylate synthesis for the establishment of TMBP inhibition. It is assumed that thymidylate synthesis in the presence of TMBP is necessary for the depletion of THF and subsequent inhibition of protein and nucleic acid synthesis. This is supported by the next two experiments in which it is shown that TMBP has little effect on protein synthesis unless thymidylate synthesis occurs. In the first experiment, a thymine auxotroph is shown to synthesize protein in the presence of TMBP at 80% of the control rate (Fig. 3) . In the second experiment, FUdR, a specific inhibitor of thymidylate synthetase (4), 10 thetase in a manner analogous to that described by Blakely for the enzyme from Streptococcus faecalis (2) . The inhibition was competitive ( Fig.   IOA ) with a Ki of 75 pM (Fig. lOB) synthesis, whatever its rate, in stringent cells.
To conclude, it has been shown that TMBP inhibits RNA, DNA, and protein synthesis in E. coli. This is consistent with the generalized THF deficiency rather than single inhibition of thymidylate synthesis, purine supply, or protein initiation. Although the cause of the THF deficiency is due to inhibition of DHF reductase and dependent on the action of thymidylate synthetase, the consequences are not restricted to a single system, and it is difficult to establish whether any one of the several reactions utilizing THF is a primary target.
